Bristol Myers (BMY) Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- 2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
- Big Pharma rejoins the mental health field, WSJ says
- Cautious Outlook on Bristol-Myers Squibb Due to Cobenfy’s Uncertain Future and Reliance on Trial Outcomes
- Spotify upgraded, Freshpet downgraded: Wall Street’s top analyst calls
- Morning Movers: 2seventy Bio skyrockets following acquisition by Bristol Myers